How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about ripretinib

Marketing authorisation indication

2.1 Ripretinib (Qinlock, Deciphera Pharmaceuticals) is indicated for 'the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for ripretinib.

Price

2.3 The list price of ripretinib is £18,400 per 30-day supply (excluding VAT; company submission). This is based on 150 mg dose once daily (three 50 mg tablets). The company has a commercial arrangement, which would have applied if ripretinib had been recommended.